Clinical Significance of CYP11B2 Immunostaining in Unilateral Primary Aldosteronism

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2023 Dec 5

PMID 38051154

Authors

Marianna Viukari

Helena Leijon

Tiina Vesterinen

Sanni Soderlund

Paivi Hamalainen

Iina Yliaska

Paivi Rautiainen

Reeta Rintamaki

Minna Soinio

Ilkka Porsti

Pasi I Nevalainen

Niina Matikainen

Affiliations

Soon will be listed here.

Abstract

Objective: The associations between adrenal histopathology, lateralization studies, and surgical outcomes in primary aldosteronism remain poorly characterized. We examined the value of immunohistochemical analysis of CYP11B2 for evaluation of adrenalectomy outcomes after anatomical versus functional subtyping.

Design: A retrospective multicenter study of 277 patients operated for primary aldosteronism who had an adrenalectomy sample available in the Finnish biobanks from 1 January 2000 to 31 December 2019. Adrenal slides from biobanks were analyzed centrally after CYP11B2 and CYP11B1 staining. Clinical data were obtained from patient registries. Histopathological diagnosis and cure after surgery were assessed as outcome measures.

Results: Re-evaluation with CYP11B2 staining changed the histopathological diagnosis in 91 patients (33%). The presence of a CYP11B2-positive adenoma and the use of functional subtyping independently predicted clinical cure of primary aldosteronism. CYP11B2-positive <7 mm nodules were more frequent in patients without clinical cure, whereas CYP11B2-positive micronodules were common in all patients and had no impact on adrenalectomy outcomes. Small CYP11B2-positive nodules and micronodules were equally prevalent regardless of the subtyping method applied. Clinical cure rates were lower and CYP11B2-negative adenomas more common after adrenalectomy based on anatomical imaging than functional studies.

Conclusions: Incorporating CYP11B2 staining in histopathological diagnosis enhances the prediction of surgical outcomes in primary aldosteronism. A finding of CYP11B2-positive adenoma is indicative of cure of primary aldosteronism, whereas smaller CYP11B2-positive nodules associate with poorer results at postoperative evaluation. Functional subtyping methods decrease the operations of CYP11B2-negative adenomas and are superior to anatomical imaging in identifying unilateral primary aldosteronism.

References

Turcu A, Yang J, Vaidya A . Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022; 18(11):665-682. DOI: 10.1038/s41574-022-00730-2. View

Spath M, Korovkin S, Antke C, Anlauf M, Willenberg H . Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol. 2011; 164(4):447-55. DOI: 10.1530/EJE-10-1070. View

Meyer L, Handgriff L, Lim J, Udager A, Kinker I, Ladurner R . Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension. 2021; 78(3):738-746. DOI: 10.1161/HYPERTENSIONAHA.121.17348. View

Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A . Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol. 2018; 3(8):768-774. PMC: 6143072. DOI: 10.1001/jamacardio.2018.2003. View

Rubello D, Bui C, Casara D, Gross M, Fig L, Shapiro B . Functional scintigraphy of the adrenal gland. Eur J Endocrinol. 2002; 147(1):13-28. DOI: 10.1530/eje.0.1470013. View

Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A . Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. Hypertension. 2018; 72(3):658-666. PMC: 6202119. DOI: 10.1161/HYPERTENSIONAHA.118.11568. View

Rossi G, Crimi F, Rossitto G, Amar L, Azizi M, Riester A . Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. J Clin Endocrinol Metab. 2021; 106(11):e4340-e4349. DOI: 10.1210/clinem/dgab482. View

Yan Y, Sun H, Qi Y . Prognosis of adrenalectomy guided by computed tomography versus adrenal vein sampling in patients with primary aldosteronism: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2022; 24(2):106-115. PMC: 8845452. DOI: 10.1111/jch.14395. View

Arlt W, Lang K, Sitch A, Dietz A, Rhayem Y, Bancos I . Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight. 2017; 2(8). PMC: 5396526. DOI: 10.1172/jci.insight.93136. View

10.

Velema M, de Nooijer A, Burgers V, Hermus A, Timmers H, Lenders J . Health-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review. Horm Metab Res. 2017; 49(12):943-950. DOI: 10.1055/s-0043-121706. View

11.

Puar T, Khoo C, Tan C, Tong A, Tan M, Teo A . 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial. J Hypertens. 2022; 40(6):1179-1188. DOI: 10.1097/HJH.0000000000003132. View

12.

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

13.

Isojarvi J, Viukari M, Porsti I, Leijon H, Vesterinen T, Seppanen M . Lateralization in C-Metomidate PET and outcome of adrenalectomy in primary aldosteronism. Endocrinol Diabetes Metab. 2022; 5(6):e368. PMC: 9659653. DOI: 10.1002/edm2.368. View

14.

Chen S, Chen J, Huang W, Puar T, Kek P, Chueh J . Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur J Endocrinol. 2022; 187(6):S47-S58. DOI: 10.1530/EJE-22-0375. View

15.

Viukari M, Kokko E, Porsti I, Leijon H, Vesterinen T, Hinkka T . Adrenal androgens versus cortisol for primary aldosteronism subtype determination in adrenal venous sampling. Clin Endocrinol (Oxf). 2022; 97(3):241-249. PMC: 9544970. DOI: 10.1111/cen.14691. View

16.

Soinio M, Luukkonen A, Seppanen M, Kemppainen J, Seppanen J, Pienimaki J . Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020; 183(6):539-550. PMC: 8045447. DOI: 10.1530/EJE-20-0532. View

17.

Dekkers T, Prejbisz A, Schultze Kool L, Groenewoud H, Velema M, Spiering W . Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016; 4(9):739-746. DOI: 10.1016/S2213-8587(16)30100-0. View

18.

Williams T, Gong S, Tsurutani Y, Tezuka Y, Thuzar M, Burrello J . Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study. Lancet Diabetes Endocrinol. 2022; 10(11):769-771. DOI: 10.1016/S2213-8587(22)00253-4. View

19.

Burton T, Mackenzie I, Balan K, Koo B, Bird N, Soloviev D . Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2011; 97(1):100-9. DOI: 10.1210/jc.2011-1537. View

20.

Lin J, Peng K, Kuo Y, Liu H, Tan C, Lin Y . Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism. Endocr Relat Cancer. 2021; 29(2):59-69. DOI: 10.1530/ERC-21-0287. View